Gerresheimer, an innovative systems and solutions provider and global partner to the pharma, biotech and cosmetics industries, has published its 2025 annual and consolidated financial statements, which were issued with an unqualified audit opinion.
The publication had been postponed due to internal investigations, now completed, regarding revenues and accounting practices in financial years 2024 and 2025. Incorrect entries have been thoroughly reviewed and corrected in the financial statements now available. The Gerresheimer Group’s revenues rose by 16.6 percent to EUR 2.321 billion in financial year 2025 due to the first-time consolidation of Bormioli Pharma (2024: 1.991 billion euros, adjusted).
Adjusted EBITDA reached EUR 384.0 million (2024: EUR 388.0 million, adjusted). Taking currency-adjustments into account, the adjusted EBITDA margin stood at 16.8 percent (2024: 19.4 percent, adjusted, pro forma).
Compared to the combined, currency-adjusted pro forma figures from the previous year, revenue grew by 0.3percent. Organic growth was driven primarily by the Plastics & Devices division, and within that division, particularly by strong demand for drug delivery devices. The Primary Packaging Glass division, on the other hand, was impacted by a decline in demand for primary packaging for cosmetics and pharmaceutical oral liquids. Here, organic revenues and adjusted EBITDA declined compared to the combined pro forma figures from the previous year.
For the current financial year 2026, Gerresheimer expects revenues to be in the lower half of the EUR 2.3 to 2.4 billion range and an adjusted EBITDA margin between 17 and 18 percent.
Highlights
- Revenue of EUR 2.3 billion, adjusted EBITDA of EUR 384 million
- Organic revenue growth of +0.3 percent, adjusted EBITDA margin at 16.8 percent
- Closing of the sale of Centor and comprehensive debt refinancing planned for this year
- Implementation of the transformation program (gto) for gradual margin improvement